Cell therapy company Cynata Therapeutics (ASX:CYP) has announced the appointment of Janine Rolfe as an independent non-executive director.
“I am delighted to be joining Cynata at a time when the Company’s robust clinical product development pipeline is advancing rapidly, and the Company’s commercial and strategic opportunities continue to progress. Cynata is the global leader in the development of induced pluripotent stem cell (iPSC) derived cell therapy products and I am very excited to be involved in the next stage of the Company’s growth,” said Ms Rolfe.
Ms Rolfe has over two decades of legal, governance and management experience across multiple sectors, including highly regulated industries and complex global businesses.
Before recently transitioning as a professional non-executive director, Ms Rolfe’s last executive position was general counsel and company secretary of Link Group. Prior to that, she founded Company Matters and worked both in-house (Qantas Airways Limited) and in private practice (Mallesons Stephen Jaques, now King and Wood Mallesons).
“Cynata continues to build a team with proven leadership capabilities and with Janine joining the Board of Directors we welcome a new skill set and contemporary outlook. Janine’s extensive experience in M&A, governance and growth businesses will add a new depth of talent to the Company at a very exciting time in our maturation. We welcome Janine to the Board and look forward to her contributions toward the advancement of Cynata and the flourishing Cymerus product pipeline,” added Cynata chair, Dr Geoff Brooke.